80795-53-5

Usage

Uses

Used in Organic Synthesis:
Methyl 3,5-di-O-benzyl-a-D-ribofuranoside is used as a building block for the synthesis of various organic compounds. Its selective protection and methylation allow for the controlled formation of complex molecules with potential applications in various industries.
Used in Medicinal Chemistry:
Methyl 3,5-di-O-benzyl-a-D-ribofuranoside is used as a key intermediate in the development of new pharmaceuticals. Its unique structure and reactivity enable the design and synthesis of novel drug candidates targeting specific biological pathways and diseases.
Used in the Study of Ribofuranose-Containing Molecules:
Methyl 3,5-di-O-benzyl-a-D-ribofuranoside is used as a research tool to investigate the structure and function of ribofuranose-containing molecules in biological systems. Its selective protection and modification provide insights into the role of ribofuranose in RNA and other biological molecules, contributing to a better understanding of their mechanisms of action and potential therapeutic applications.

Upstream product

• 75-24-1 trimethylaluminum 
• 79083-29-7 (2R,3R,4R,5S)-3,4-bis(benzyloxy)-2-((benzyloxy)methyl)-5-methoxytetrahydrofuran 
• 64363-77-5 methyl 2,3,5-tri-O-benzyl-D-ribofuranoside 
• 532-20-7 D-Ribose 
• 52485-92-4 methyl α-D-ribofuranoside 
• 100-44-7 benzyl chloride 
• 1824-96-0 methyl ribofuranoside 

Downstream Products

• 885592-69-8 (2S,4R,5R)-4-(benzyloxy)-5-((benzyloxy)methyl)-2-methoxydihydrofuran-3(2H)-one 
• 1363735-81-2 2-[N-(4-methoxybenzyl)amino]-3-methyl-5-{2'-O-[2-(N,N-dibenzyl)aminoethyl]-3',5'-di-O-benzyl-β-D-ribofurano-1'-yl}pyridine 
• 1363735-83-4 2-amino-3-methyl-5-{2'-O-[2-(N,N-dibenzyl)aminoethyl]-3',5'-di-O-benzyl-β-D-ribofuranosyl}pyridine 
• 1363735-85-6 2-amino-3-methyl-5-{2'-O-[2-(N,N-dibenzyl)aminoethyl]-β-D-ribofuranosyl}pyridine 
• 1363735-66-3 methyl 2-O-(2-hydroxyethyl)-3,5-di-O-benzyl-α-D-ribofuranoside 
• 1363735-68-5 methyl 2-O-(2-phthalimidoethyl)-3,5-di-O-benzyl-α-D-ribofuranoside 
• 1363735-64-1 methyl 2-O-(methoxycarbonylmethyl)-3,5-di-O-benzyl-α-D-ribofuranoside 
• 1439900-71-6 (Z)-N-((2S,4S,5R)-4-(benzyloxy)-5-((benzyloxy)methyl)-2-methoxydihydrofuran-3(2H)-ylidene)-2-methylpropane-2-sulfinamide 
• 1255860-29-7 (2S,3R,4R,5R)-3-allyl-4-(benzyloxy)-5-(benzyl-oxymethyl)-2-methoxytetrahydrofuran-3-yl benzoate 
• 1255860-30-0 1-((2R,3R,4R,5R)-3-allyl-4-(benzyloxy)-5-(benzyloxymethyl)-3-hydroxytetra-hydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione 
• 1255860-31-1 1-[(2R,3R,4R,5R)-4-(benzyloxy)-5-(benzyloxy-methyl)-3-hydroxy-3-(2-hydroxyethyl)tetrahydrofuran-2-yl]pyrimidine-2,4(1H,3H)-dione 
• 1255860-32-2 1-[(4R,5R,7R,8R)-8-(benzyloxy)-7-(benzyloxy-methyl)-1,6-dioxaspiro[3.4]octan-5-yl]pyrimidine-2,4(1H,3H)-dione 
• 1255860-34-4 (2S)-butyl-2-(((((4R,5R,7R,8R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-8-hydroxy-1,6-dioxa-spiro[3.4]octan-7-yl)-methoxy)(phenoxy)phosphoryl)amino)propanoate 
• 1363735-76-5 2-O-[2-(N,N-dibenzyl)aminoethyl]-3,5-di-O-benzyl-D-ribolactone 

Relevant academic research and scientific papers

HCV POLYMERASE INHIBITORS

The invention provides compounds of the formula:(I) which are of use in the treatment or prophylaxis of hepatitis C virus infection, and related aspects.

HCV Polymerase Inhibitors

The invention provides compounds of the formula: which are of use in the treatment or prophylaxis of hepatitis C virus infection, and related aspects.

Uracyl Spirooxetane Nucleoside Phosphoramidates

This invention relates to a stereochemically pure uracyl spirooxetane nucleoside phosphoramidate which inhibits the hepatitis C virus (HCV).

Uracyl Spirooxetane Nucleoside Phosphoramidates

This invention relates to a stereochemically pure uracyl spirooxetane nucleoside phosphoramidate useful in the treatment of patients infected with the hepatitis C virus (HCV).

Synthesis and properties of triplex-forming oligonucleotides containing 2′-O-(2-methoxyethyl)-5-(3-aminoprop-1-ynyl)-uridine

2′-O-(2-Methoxyethyl)-5-(3-aminoprop-1-ynyl)-uridine phosphoramidite (MEPU) has been synthesized from d-ribose and 5-iodouracil and incorporated into triplex-forming oligonucleotides (TFOs) by automated solid-phase oligonucleotide synthesis. The TFOs gave very high triplex stability with their target duplexes as measured by ultraviolet/fluorescence melting and DNase I footprinting. The incorporation of MEPU into TFOs renders them resistant to degradation by serum nucleases.

Efficient synthesis of methyl 3,5-di-O-benzyl-α-D-ribofuranoside and application to the synthesis of 2′-C-β-alkoxymethyluridines

Methyl 3,5-di-O-arylmethyl-α-D-ribofuranosides have been used extensively as synthons to construct 2'-C-branched ribonucleosides. Herein, we describe efficient access to methyl 3,5-di-O-arylmethyl-α-D- ribofuranosides (aryl: 2-ClC6H4, 3-ClC6H 4, 4-ClC6H4, 4-BrC6H4, 2,4-Cl2C6H3, Ph) in 72-82% yields from methyl D-ribofuranoside. We also demonstrate efficient access to the versatile precursor methyl 3,5-di-O-benzyl-α-D-ribofuranoside (3f) and the synthesis of 2′-C-β-methoxymethyl- and 2′-C-β-ethoxymethyluridine in six steps from 3f with overall yields of 18% and 32%, respectively.

THERAPEUTIC FUROPYRIMIDINES AND THIENOPYRIMIDINES

The invention provides compounds of formula I, II, and III as described herein, as well as pharmaceutical compositions comprising the compounds, and synthetic methods and intermediates that are useful for preparing the compounds. The compounds of formula I, II, and III are useful as anti-viral agents and/or as anti-cancer agents.

Alkylalanes and methyl furanosides: regioselective O-debenzylation or acetal cleavage

Perbenzylated methyl pentofuranosides were submitted to the action of three alkylalanes and regioselective debenzylation at O-2 of the four pentoses was observed when choosing the right match between anomeric configuration and aluminium reagent. Diisobuty